EcoDrugPlus

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSSFOG00015022953
Gene Symbol: CHRM2A
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSSFOG00015022934
Gene Symbol: CHRNA7A
1 Cross references
248 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSSFOG00015028768
Gene Symbol: F2R
3 Cross references
154 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSSFOG00015007558
Gene Symbol: F3
3 Cross references
241 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSSFOG00015008184
Gene Symbol: LOC108937772
3 Cross references
78 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSSFOG00015008132
Gene Symbol: F10
1 Cross references
240 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSSFOG00015011302
Gene Symbol: CCDC6
3 Cross references
218 Possible Orthologues:

Coiled-Coil Domain-Containing Protein 6

Ensembl ID : ENSSFOG00015026711
Gene Symbol: LOC108932852
3 Cross references
217 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSSFOG00015021247
Gene Symbol: LOC108921331
2 Cross references
306 Possible Orthologues:

Colony Stimulating Factor 1 Receptor

Ensembl ID : ENSSFOG00015014696
Gene Symbol: CSF1R
3 Cross references
8 Possible Orthologues:

Complement Factor D-Like

Ensembl ID : ENSSFOG00015027583
Gene Symbol: LOC108919827
3 Cross references
133 Possible Orthologues:

Corticotropin Releasing Hormone Receptor 1

Ensembl ID : ENSSFOG00015020970
Gene Symbol: CRHR1
3 Cross references
162 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).